文献速递病毒性肝炎

全基因组关联研究识别慢性乙型肝炎患者对(聚乙二醇)干扰素早期和持续应答相关的遗传变异:GIANT-B研究

Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study.
PubMed 文献 · Clin Infect Dis · 2019-01-01

该研究为全基因组关联研究(GWAS),纳入1144例接受(聚乙二醇)干扰素治疗至少12周的慢性乙型肝炎患者,其中1058例纳入分析。共282例(31%)获得应答,4%实现HBsAg清除。按HBeAg状态分层分析发现,PRELID2 rs371991与HBeAg阳性患者应答相关,G3BP2 rs3821977与HBeAg阴性患者应答相关,但均未达到全基因组显著性。

要点

  • PRELID2 rs371991与HBeAg阳性CHB患者干扰素应答相关(P=3.44×10-6)。
  • G3BP2 rs3821977与HBeAg阴性CHB患者干扰素应答相关(P=2.46×10-6)。
  • G3BP2 G等位基因在IFNα和TLR8刺激后与IP-10、IL-10降低及IL-8升高相关。

核心结论

  • 虽未发现全基因组显著关联,但该GWAS识别了与CHB患者(Peg)IFN应答相关的遗传变异。

研究设计与样本

  • 全基因组关联研究(GWAS),纳入来自欧洲、亚洲和北美21个中心的接受(Peg)IFN至少12周±核苷(酸)类似物的CHB患者。
  • 共1144例患者,其中1058例(92%)纳入GWAS分析。

主要发现

  • 共282例(31%)患者获得应答,4%实现HBsAg清除。
  • 按HBeAg状态分层并调整年龄、性别和4个祖先成分后,PRELID2 rs371991与HBeAg阳性患者应答相关(B=-0.74,SE=0.16,P=3.44×10-6)。
  • PRELID2在HBeAg阴性患者中长期应答中被交叉验证。
  • G3BP2 rs3821977与HBeAg阴性患者应答相关(B=1.13,SE=0.24,P=2.46×10-6)。
  • 在健康对照外周血单个核细胞经IFNα和TLR8刺激后,G3BP2 G等位基因与IP-10和IL-10蛋白产生减少及IL-8产生增多相关。

关键数值与推荐

  • 应答定义:治疗结束后24周时HBeAg清除且HBV DNA<2000 IU/mL,或HBeAg阴性患者HBV DNA<2000 IU/mL。
  • PRELID2 rs371991:HBeAg阳性患者,B=-0.74,SE=0.16,P=3.44×10-6。
  • G3BP2 rs3821977:HBeAg阴性患者,B=1.13,SE=0.24,P=2.46×10-6。

临床怎么用

  • 当前发现可能为基因多态性指导的临床咨询铺平道路,涉及(Peg)IFN治疗及自然史背景。
  • 可能为新的免疫调节治疗提供依据。

局限性

  • 未发现全基因组显著关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: (Pegylated) Interferon ([Peg]IFN) therapy leads to response in a minority of chronic hepatitis B (CHB) patients. Host genetic determinants of response are therefore in demand. METHODS: In this genome-wide association study (GWAS), CHB patients, treated with (Peg)IFN for at least 12 weeks ± nucleos(t)ide analogues within randomized trials or as standard of care, were recruited at 21 centers from Europe, Asia, and North America. Response at 24 weeks after (Peg)IFN treatment was defined as combined hepatitis B e antigen (HBeAg) loss with hepatitis B virus (HBV) DNA <2000 IU/mL, or an HBV DNA <2000 IU/mL for HBeAg-negative patients. RESULTS: Of 1144 patients, 1058 (92%) patients were included in the GWAS analysis. In total, 282 (31%) patients achieved the response and 4% hepatitis B surface antigen (HBsAg) loss. GWAS analysis stratified by HBeAg status, adjusted for age, sex, and the 4 ancestry components identified PRELID2 rs371991 (B= -0.74, standard error [SE] = 0.16, P = 3.44 ×10-6) for HBeAg-positive patients. Importantly, PRELID2 was cross-validated for long-term response in HBeAg-negative patients. G3BP2 rs3821977 (B = 1.13, SE = 0.24, P = 2.46 × 10-6) was associated with response in HBeAg-negative patients. G3BP2 has a role in the interferon pathway and was further examined in peripheral blood mononuclear cells of healthy controls stimulated with IFNα and TLR8. After stimulation, less production of IP-10 and interleukin (IL)-10 proteins and more production of IL-8 were observed with the G3BP2 G-allele. CONCLUSIONS: Although no genome-wide significant hits were found, the current GWAS identified genetic variants associated with (Peg)IFN response in CHB. The current findings could pave the way for gene polymorphism-guided clinical counseling, both in the setting of (Peg)IFN and the natural history, and possibly for new immune-modulating therapies. CLINICAL TRIALS REGISTATION: NCT01401400.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Brouwer WP, Chan HLY, Lampertico P, et al. Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. Clin Infect Dis. 2019. PMID: 30715261. doi:10.1093/cid/ciz084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。